MADRIGAL PHARMACEUTICALS INC (MDGL)
US5588681057 - Common Stock
MADRIGAL PHARMACEUTICALS INC
NASDAQ:MDGL (5/9/2024, 7:04:45 PM)
After market: 206.92 0 (0%)206.92
-1.12 (-0.54%)
Company Profile
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania and currently employs 92 full-time employees. The company went IPO on 2007-02-06. The firm is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The firm's product candidate, resmetirom, is a proprietary, liver-directed, selective thyroid hormone receptor-B (THR-B), agonist being developed as a once-daily oral pill for the treatment of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). NASH is a liver disease that affects people with metabolic diseases, such as obesity and diabetes and non-alcoholic fatty liver disease (NAFLD).
Company Info
MADRIGAL PHARMACEUTICALS INC
200 Barr Harbor Dr Ste 400
West Conshohocken PENNSYLVANIA 19428
P: 14043809263
CEO: Paul A. Friedman
Employees: 92
Website: https://www.madrigalpharma.com/
MDGL News
2 days ago - InvestorPlaceMDGL Stock Earnings: Madrigal Pharmaceuticals Misses EPS for Q1 2024MDGL stock results show that Madrigal Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.
On March 14, 2024, received U.S. FDA approval of Rezdiffra™ (resmetirom) for the treatment of patients with noncirrhotic nonalcoholic steatohepatitis...
CONSHOHOCKEN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- The Madrigal team is shocked and saddened to learn of the passing of Dr. Stephen Harrison. We...
17 days ago - Market News VideoMadrigal Pharmaceuticals Becomes Oversold (MDGL)18 days ago - TheNewswire.com6 Stocks Positioned to Soar as Investors Focus on MASHInvestors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it's easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class of drugs was originally designed to manage blood sugar levels in diabetics but was expanded to treat obesity, an even bigger market. JP Morgan analyst Richard Vosser estimated the global obesity drug market will reach $71 billion by 2032.
CONSHOHOCKEN, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company pursuing novel...
MDGL Twits
Here you can normally see the latest stock twits on MDGL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
